AI vs. Opioids: A New Alliance Aims to Close the Patient Care Gap

DENVER, CO – June 15, 2026 – In a strategic move that signals a significant maturation in the healthcare technology market, AI-powered clinical intelligence firm cliexa and opioid stewardship leader OpiSafe have announced a partnership. The collaboration will yield a single, integrated platform designed to combat the opioid crisis not merely at the point of prescription, but across the entire continuum of care. This alliance is more than a product launch; it’s a structural response to one of modern healthcare’s most fragmented and devastating challenges, reflecting a broader industry pivot toward intelligent, interoperable ecosystems that work within, not against, established clinical workflows.

For years, the fight against opioid misuse has been hampered by siloed data and disconnected care pathways. A provider might identify a patient at risk, but the tools to manage a safe reduction in medication or refer them to behavioral health services often exist in separate systems, creating friction and gaps through which patients can fall. The cliexa-OpiSafe partnership aims to weld these broken links into a seamless chain, embedding a sophisticated clinical reasoning layer directly into the electronic medical record (EMR).

A New Blueprint for Opioid Stewardship

The strategic rationale behind this partnership is rooted in a stark reality: the opioid crisis, which costs the U.S. an estimated $78.5 billion annually in direct healthcare expenses and lost productivity, is fundamentally a systems problem. With over 10 million Americans misusing prescription opioids last year, the need for a proactive, unified solution has never been more acute. This new platform combines cliexa’s validated AI for predicting Opioid Use Disorder (OUD) risk with OpiSafe’s patented technologies for managing medication tapering and coordinating treatment referrals.

"The opioid crisis remains one of healthcare's most complex and costly challenges because providers often lack a connected pathway from risk identification to intervention," said Mehmet Kazgan, Founder and Chief Executive Officer of cliexa. "By combining our capabilities, cliexa and OpiSafe are delivering a unified platform that helps clinicians identify risk earlier, guide safer prescribing decisions, and connect patients to appropriate treatment before adverse outcomes occur."

This integration brings together two specialized innovators. cliexa, a graduate of the prestigious Mayo Clinic Platform_Accelerate program, has earned qualification for its OUD prediction model, which transforms fragmented patient data into actionable risk scores. OpiSafe, a market presence since 2015, has focused on the practical application of safe prescribing guidelines, building patented workflows that help clinicians manage complex tapering schedules and document their rationale.

From Prediction to Practice: Inside the Integrated Platform

The power of the combined offering lies in its three-pronged approach, all delivered within the clinician's native EMR environment. First is the AI-powered risk prediction. Validated by the Mayo Clinic Platform, cliexa's model analyzes clinical, claims, and patient-generated data to produce a four-tier risk stratification. Crucially, this is not a 'black box' algorithm; the platform provides explainable contributing factors, showing a provider why a patient is flagged as medium or high risk, thereby building trust and supporting confident clinical judgment.

Second, the platform operationalizes intervention. It integrates OpiSafe’s patented opioid tapering management tools, which translate evidence-based guidelines into actionable, patient-specific plans. This automates the complex process of safely reducing opioid exposure, monitoring patient progress, and documenting every step, significantly reducing the administrative load on already-strained providers.

Third, and perhaps most critically, it closes the loop on care coordination. Using OpiSafe’s patented referral technology, the system streamlines the process of connecting a patient with behavioral health specialists or addiction treatment centers. This 'closed-loop' referral management ensures that a recommendation for help is not just made, but tracked until the patient is successfully connected with the appropriate services.

"Healthcare organizations increasingly need connected clinical intelligence platforms that can identify risk, guide evidence-based interventions, and support coordinated treatment pathways within existing workflows," noted Robert J. Valuck, CEO of OpiSafe's parent company, RxAssurance. This integration, he explained, expands the platform's capabilities to support a more "proactive, data-driven approach" to both opioid stewardship and the broader landscape of behavioral health management.

Closing the Care Gap for Patients and Providers

By embedding this entire workflow—from prediction to tapering to referral—into the EMR, the platform directly addresses the operational friction that undermines effective care. For clinicians, it means fewer logins, less manual data entry, and the automation of compliance tasks like Prescription Drug Monitoring Program (PDMP) checks. Actionable intelligence is delivered at the point of care, not in a separate dashboard, allowing for real-time adjustments to treatment plans.

For health systems, the benefits extend to regulatory compliance and financial stability. The platform is designed to provide payer-aligned decision support, ensuring that documentation meets the requirements for quality reporting and reimbursement. In an era where value-based care models are gaining traction, demonstrating proactive, evidence-based management of high-risk patient populations is becoming essential for financial health. By helping prevent the catastrophic downstream costs of untreated OUD, the solution presents a compelling clinical and financial value proposition.

Ultimately, the partnership between cliexa and OpiSafe represents a critical evolution in digital health. It moves beyond simply providing data to delivering intelligence, and beyond identifying problems to actively managing solutions. By creating a cohesive, intelligent workflow that bridges the gap between prescribing, pain management, and behavioral health, this alliance is not just launching a new product—it is offering a more hopeful and effective blueprint for navigating one of the greatest public health challenges of our time.